| Filed On | Filing |
|---|---|
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) |
| 28 Oct 2026 | SCHEDULE 13G/A |
| 19 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a written notice (the “First Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) in... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) |
| 11 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | SCHEDULE 13G |
| 14 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2026, Mereo BioPharma Group plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed. Of the ordinary shares entitled to vote, there were 436,766,255 ord... |
| 12 May 2026 |
8-K/A: Results of Operations and Financial Condition
London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026... |
| 12 May 2026 | 10-Q |
| 12 May 2026 |
8-K: Completion of Acquisition or Disposition of Assets
London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026... |
| 09 Apr 2026 | ARS |
| 09 Apr 2026 | Proxy statement: annual meeting on May 14, 2026 |
| 27 Mar 2026 | PRE 14A |
| 27 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 26, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma plc. (the “Company”) that she will not stand for re-election as a Director of the Board of Directors (the “Board”) of the Company at the Company’s 2026 annual general meeti... |
| 19 Mar 2026 | 10-K |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing |
Loading...